Smith RA, Dumas J, Adnane L, Wilhelm SM (2006) Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem 6(11):1071–1089
Article
CAS
Google Scholar
Williams TE, Subramanian S, Verhagen J, McBride CM, Costales A, Sung L, Antonios-McCrea W, McKenna M, Louie AK, Ramurthy S (2015) Discovery of RAF265: a potent mut-B-RAF inhibitor for the treatment of metastatic melanoma. ACS Med Chem Lett 6(9):961–965
Article
CAS
Google Scholar
Li Z, Jiang J-D, Kong W-J (2014) Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation. Biol Pharm Bull 37(11):1766–1775
Article
CAS
Google Scholar
Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14(7):455–467
Article
CAS
Google Scholar
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6):683–695
Article
CAS
Google Scholar
Luo C, Xie P, Marmorstein R (2008) Identification of BRAF inhibitors through in silico screening. J Med Chem 51(19):6121–6127
Article
CAS
Google Scholar
Uehling DE, Harris PA (2015) Recent progress on MAP kinase pathway inhibitors. Bioorg Med Chem Lett 25(19):4047–4056
Article
CAS
Google Scholar
Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242–3249
Article
CAS
Google Scholar
Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5):856–862
Article
CAS
Google Scholar
Fransén K, Klintenäs M, Österström A, Dimberg J, Monstein H-J, Söderkvist P (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25(4):527–533
Article
Google Scholar
Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690
Article
Google Scholar
Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46(2):161–165
Article
CAS
Google Scholar
Fiskus W, Mitsiades N (2016) B-Raf inhibition in the clinic: present and future. Annu Rev Med 67:29–43
Article
CAS
Google Scholar
Dienstmann R, Tabernero J (2011) BRAF as a target for cancer therapy. Anticancer Agents Med Chem 11(3):285–295
Article
CAS
Google Scholar
Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10(1):23
Article
CAS
Google Scholar
Murray CW, Rees DC (2016) Opportunity knocks: organic chemistry for fragment-based drug discovery (FBDD). Angew Chem Int Ed 55(2):488–492
Article
CAS
Google Scholar
Jang S, Atkins M (2014) Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 95(1):24–31
Article
CAS
Google Scholar
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5(10):835–844
Article
CAS
Google Scholar
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
Article
CAS
Google Scholar
Zhan Y, Dahabieh MS, Rajakumar A, Dobocan MC, M’Boutchou M-N, Goncalves C, Lucy SL, Pettersson F, Topisirovic I, van Kempen L (2015) The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. J Invest Dermatol 135(5):1368–1376
Article
CAS
Google Scholar
Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R (2013) Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 133(8):2041–2049
Article
CAS
Google Scholar
Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu Z-X (2012) First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 18(17):4806–4819
Article
CAS
Google Scholar
Helvind NM, Hölmich LR, Smith S, Glud M, Andersen KK, Dalton SO, Drzewiecki KT (2015) Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24 059 melanoma cases. JAMA Dermatol 151(10):1087–1095
Article
Google Scholar
Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Diba CS, Eser S, Gavric Z, Primic-Zakelj M (2016) Disparities in melanoma incidence and mortality in South-Eastern Europe: increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer 55:47–55
Article
Google Scholar
Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH (2012) Structure-based virtual screening for drug discovery: a problem-centric review. AAPS J 14(1):133–141
Article
CAS
Google Scholar
Schmidt T, Bergner A, Schwede T (2014) Modelling three-dimensional protein structures for applications in drug design. Drug Discov Today 19(7):890–897
Article
CAS
Google Scholar
Lee JA, Roh EJ, Oh C-H, Lee SH, Sim T, Kim JS, Yoo KH (2015) Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line. J Enzyme Inhib Med Chem 30(4):607–614
Article
Google Scholar
Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26(22):3279
Article
CAS
Google Scholar
Ulrich B, Norman L (1982) Molecular mechanics (ACS monograph 177). Am Chem Soc, Washington, DC
Google Scholar
Molegro A (2011) MVD 5.0 Molegro Virtual Docker, A CLC Bio Company
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62(23):6997–7000
CAS
PubMed
Google Scholar
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596
Article
CAS
Google Scholar
Choi W-K, El-Gamal MI, Choi HS, Baek D, Oh C-H (2011) New diarylureas and diarylamides containing 1, 3, 4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. Eur J Med Chem 46(12):5754–5762
Article
CAS
Google Scholar
Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49(11):3315–3321
Article
CAS
Google Scholar
Martinez-Mayorga K, Madariaga-Mazon A, Medina-Franco JL, Maggiora G (2020) The impact of chemoinformatics on drug discovery in the pharmaceutical industry. Expert Opin Drug Discov 15(3):293–306
Article
CAS
Google Scholar
Adedirin O, Uzairu A, Shallangwa GA, Abechi SE (2018) Optimization of the anticonvulsant activity of 2-acetamido-N-benzyl-2-(5-methylfuran-2-yl) acetamide using QSAR modeling and molecular docking techniques. Beni-Suef Univ J Basic Appl Sci 7(4):430–440
Article
Google Scholar
Umar BA, Uzairu A, Shallangwa GA, Uba S (2019) Rational drug design of potent V600E-BRAF kinase inhibitors through molecular docking simulation. J Eng Exact Sci 5(5):0469–0481
Article
Google Scholar
Kok-Yong S, Lawrence L (2015) In: Ahmed TA (ed) Drug distribution and drug elimination. Basic pharmacokinetic concepts and some clinical applications. InTech, Rijeka, pp 99–116
Google Scholar
Šrejber M, Navrátilová V, Paloncýová M, Bazgier V, Berka K, Anzenbacher P, Otyepka M (2018) Membrane-attached mammalian cytochromes P450: an overview of the membrane’s effects on structure, drug binding, and interactions with redox partners. J Inorg Biochem 183:117–136
Article
Google Scholar
Thapar MM, Ashton M, Lindegårdh N, Bergqvist Y, Nivelius S, Johansson I, Björkman A (2002) Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol 58(1):19–27
Article
CAS
Google Scholar